Worcestershire, United Kingdom
Worcestershire, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and provide a general business update.  The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event.  A replay of the webcast will be archived on the Company’s website for 30 days following the call. To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call. Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.


MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) A-101 40% topical solution (A-101 40%), an investigational drug, for the potential treatment of seborrheic keratosis (SK), a common skin condition. The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to permit a substantive review. The PDUFA target action date for the completion of the FDA’s review of the NDA is December 24, 2017. If approved, A-101 40% would be the first FDA-approved topical medication for the treatment of SK. “The FDA’s acceptance of our NDA for A-101 40% is a significant achievement that brings Aclaris one step closer to providing an innovative treatment option for SK patients and the physicians who treat the condition,” said Christopher Powala, Chief Operating Officer of Aclaris. “There is a significant need for a non-invasive, topical SK treatment as SK often appears in highly visible locations like the face and neck and can adversely affect patients’ emotional well-being.” About A-101 A-101 40% topical solution, an investigational drug, is a proprietary, high-concentration hydrogen peroxide formulation for the treatment of seborrheic keratosis (SK). It is being developed as a non-invasive, in-office treatment administered by physicians or other licensed health care professionals.  In clinical trials, patients treated with A-101 40% achieved statistically and clinically significant improvement in clearing SK lesions compared to placebo and with a similar adverse event profile. A-101 40% is designed to work by penetrating into the SK lesion and causing oxidative damage, which can ultimately result in the sloughing of the SK cells.  A-101 40% has been the focus of a robust clinical development program in which over 700 patients have been treated with A-101. The 45% concentration of A-101 is also in clinical development for the treatment of common warts (verruca vulgaris). About Seborrheic Keratosis Seborrheic keratosis (SK) is a skin condition that affects more than 83 million Americans and is characterized by non-cancerous lesions varying in color from light tan to dark brown or black.  SK lesions range in size from a millimeter to a few centimeters wide and usually have a slightly elevated, waxy, scaly appearance.  People with SK may be affected with just one lesion or dozens and often have a family history of SK.  SK lesions can appear anywhere on the body, except the palms, soles, and mucous membranes, and frequently appear in highly visible locations, such as the face or neck.  Though the lesions usually do not cause physical discomfort, SK can adversely affect the appearance and emotional well-being of people who have it.  Prevalence of SK increases with advancing age and the majority of patients seeking treatment from dermatologists are between 40 and 70 years of age.  Fewer than 10% of people with SK receive treatment, though it is one of the most frequent diagnoses made by dermatologists.  There are currently no FDA-approved medications for SK, and existing treatment procedures are often painful or invasive and can have undesirable outcomes like scarring or dyspigmentation. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations.  These forward-looking statements include expectations regarding Aclaris’ clinical development of A-101 for the treatment of SK. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, risks associated with maintaining its intellectual property portfolio and other risks and uncertainties that are described in Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2016 and other filings Aclaris makes with the SEC from time to time. These documents are available under the “Financial Information” section of the Investors page of Aclaris’ website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) A-101 40% topical solution (A-101 40%), an investigational drug, for the potential treatment of seborrheic keratosis (SK), a common skin condition. The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to permit a substantive review. The PDUFA target action date for the completion of the FDA’s review of the NDA is December 24, 2017. If approved, A-101 40% would be the first FDA-approved topical medication for the treatment of SK. “The FDA’s acceptance of our NDA for A-101 40% is a significant achievement that brings Aclaris one step closer to providing an innovative treatment option for SK patients and the physicians who treat the condition,” said Christopher Powala, Chief Operating Officer of Aclaris. “There is a significant need for a non-invasive, topical SK treatment as SK often appears in highly visible locations like the face and neck and can adversely affect patients’ emotional well-being.” About A-101 A-101 40% topical solution, an investigational drug, is a proprietary, high-concentration hydrogen peroxide formulation for the treatment of seborrheic keratosis (SK). It is being developed as a non-invasive, in-office treatment administered by physicians or other licensed health care professionals.  In clinical trials, patients treated with A-101 40% achieved statistically and clinically significant improvement in clearing SK lesions compared to placebo and with a similar adverse event profile. A-101 40% is designed to work by penetrating into the SK lesion and causing oxidative damage, which can ultimately result in the sloughing of the SK cells.  A-101 40% has been the focus of a robust clinical development program in which over 700 patients have been treated with A-101. The 45% concentration of A-101 is also in clinical development for the treatment of common warts (verruca vulgaris). About Seborrheic Keratosis Seborrheic keratosis (SK) is a skin condition that affects more than 83 million Americans and is characterized by non-cancerous lesions varying in color from light tan to dark brown or black.  SK lesions range in size from a millimeter to a few centimeters wide and usually have a slightly elevated, waxy, scaly appearance.  People with SK may be affected with just one lesion or dozens and often have a family history of SK.  SK lesions can appear anywhere on the body, except the palms, soles, and mucous membranes, and frequently appear in highly visible locations, such as the face or neck.  Though the lesions usually do not cause physical discomfort, SK can adversely affect the appearance and emotional well-being of people who have it.  Prevalence of SK increases with advancing age and the majority of patients seeking treatment from dermatologists are between 40 and 70 years of age.  Fewer than 10% of people with SK receive treatment, though it is one of the most frequent diagnoses made by dermatologists.  There are currently no FDA-approved medications for SK, and existing treatment procedures are often painful or invasive and can have undesirable outcomes like scarring or dyspigmentation. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations.  These forward-looking statements include expectations regarding Aclaris’ clinical development of A-101 for the treatment of SK. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, risks associated with maintaining its intellectual property portfolio and other risks and uncertainties that are described in Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2016 and other filings Aclaris makes with the SEC from time to time. These documents are available under the “Financial Information” section of the Investors page of Aclaris’ website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company, today announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) A-101 40% topical solution (A-101 40%), an investigational drug, for the potential treatment of seborrheic keratosis (SK), a common skin condition. The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to permit a substantive review. The PDUFA target action date for the completion of the FDA’s review of the NDA is December 24, 2017. If approved, A-101 40% would be the first FDA-approved topical medication for the treatment of SK. “The FDA’s acceptance of our NDA for A-101 40% is a significant achievement that brings Aclaris one step closer to providing an innovative treatment option for SK patients and the physicians who treat the condition,” said Christopher Powala, Chief Operating Officer of Aclaris. “There is a significant need for a non-invasive, topical SK treatment as SK often appears in highly visible locations like the face and neck and can adversely affect patients’ emotional well-being.” About A-101 A-101 40% topical solution, an investigational drug, is a proprietary, high-concentration hydrogen peroxide formulation for the treatment of seborrheic keratosis (SK). It is being developed as a non-invasive, in-office treatment administered by physicians or other licensed health care professionals.  In clinical trials, patients treated with A-101 40% achieved statistically and clinically significant improvement in clearing SK lesions compared to placebo and with a similar adverse event profile. A-101 40% is designed to work by penetrating into the SK lesion and causing oxidative damage, which can ultimately result in the sloughing of the SK cells.  A-101 40% has been the focus of a robust clinical development program in which over 700 patients have been treated with A-101. The 45% concentration of A-101 is also in clinical development for the treatment of common warts (verruca vulgaris). About Seborrheic Keratosis Seborrheic keratosis (SK) is a skin condition that affects more than 83 million Americans and is characterized by non-cancerous lesions varying in color from light tan to dark brown or black.  SK lesions range in size from a millimeter to a few centimeters wide and usually have a slightly elevated, waxy, scaly appearance.  People with SK may be affected with just one lesion or dozens and often have a family history of SK.  SK lesions can appear anywhere on the body, except the palms, soles, and mucous membranes, and frequently appear in highly visible locations, such as the face or neck.  Though the lesions usually do not cause physical discomfort, SK can adversely affect the appearance and emotional well-being of people who have it.  Prevalence of SK increases with advancing age and the majority of patients seeking treatment from dermatologists are between 40 and 70 years of age.  Fewer than 10% of people with SK receive treatment, though it is one of the most frequent diagnoses made by dermatologists.  There are currently no FDA-approved medications for SK, and existing treatment procedures are often painful or invasive and can have undesirable outcomes like scarring or dyspigmentation. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations.  These forward-looking statements include expectations regarding Aclaris’ clinical development of A-101 for the treatment of SK. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, risks associated with maintaining its intellectual property portfolio and other risks and uncertainties that are described in Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2016 and other filings Aclaris makes with the SEC from time to time. These documents are available under the “Financial Information” section of the Investors page of Aclaris’ website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


News Article | May 8, 2017
Site: www.prlog.org

-- HPE published a new case study,. Cartu Bank understands the need for continuous availability with more than 60% of all e-commerce transactions in the Eastern European country of Georgia going through its payment switch. Read how HPE NonStop servers with HPE Shadowbase software run mission-critical BASE24 payment engines to keep the Georgian economy running 24x7. Giorgi Ioramashvili, head of Cartu Bank's IT department, remarks, "It was important to our solution to have replication software like Shadowbase integrated with the NonStop servers. We looked at Oracle GoldenGate, which also could replicate BASE24, but because Shadowbase operates natively within the NonStop operating environment, it was more stable and easier to work with. Plus, Shadowbase was 40% to 50% less expensive than Oracle GoldenGate."To read the case study, please click: http://shadowbasesoftware.com/ banners/2017/ 04/cartu-bank- ... (http://shadowbasesoftware.com/banners/2017/04/cartu-bank-ensures-continuous-availability-of-payment-services-for-georgian-businesses/).The patented Shadowbase product line provides BASE24 classic and BASE24-eps support. All of the features and benefits of Shadowbase software are available for BASE24 application environments. For more information, please read the HPE Shadowbase BASE24 Support solution brief: http://shadowbasesoftware.com/ solution-briefs/ 2016/01/sha... Gravic, Inc. is a privately-held company located in Malvern, PA, about twenty miles west of Philadelphia, PA, USA. Gravic makes a range of computer software products for business continuity, data collection, transformation, and distribution uses. Customers of its Shadowbase data replication products include banks, financial and brokerage firms, insurance companies, stock exchanges, electric utilities, healthcare, and telecommunications companies. Hewlett Packard Enterprise directly sells and supports Shadowbase business continuity, data replication and data integration solutions under the name HPE Shadowbase. For more information, please visit ShadowbaseSoftware.com or contact your local HPE account team.


News Article | May 9, 2017
Site: www.prnewswire.com

Because brunch has become such a decidedly American pastime, it isn't surprising that the majority of winners specialize in American fare. However, Creole, French, fusion, Italian, and Mediterranean cuisines are also present on the list. "Brunch has become as synonymous with Mother's Day celebrations as it has the weekend, and the repertoire of dishes associated with the midday meal has expanded exponentially," said Caroline Potter, OpenTable Chief Dining Officer. "No longer an after-thought, this meal at these winning restaurants has become a showcase for culinary diversity, with restaurants serving everything from classic Eggs Benedict and buttermilk pancakes to succulent fried chicken with waffles, chorizo scrambles, and luxe buffets with made-to-order stations and raw bars that would delight even the most avid eaters." The 100 Best Brunch Restaurants in America list is generated solely from more than 10 million verified OpenTable diner reviews collected between March 1, 2016 and February 28, 2017. All restaurants with a minimum "overall" score and number of qualifying reviews were included for consideration. Qualifying restaurants were then scored and sorted according to the percentage of reviews for which "great for brunch" was selected as a special feature. Based on this methodology, the following restaurants, listed in alphabetical order, comprise the 100 Best Brunch Restaurants in America for 2017 according to OpenTable diners. The complete list may also be viewed at https://www.opentable.com/m/best-brunch-restaurants-in-america-2017. Diners can also read more about the 100 Best Brunch Restaurants in America as well as our #MomSquadBrunch Mother's Day giveaway by visiting the OpenTable blog. 100 Best Brunch Restaurants in America for 2017 187 Rue Principale - Emmaus, Pennsylvania ACQUA - Forest Lake, Minnesota Aksum - Philadelphia, Pennsylvania Baker House - Lake Geneva, Wisconsin Beachcomber Cafe - Crystal Cove - Newport Coast, California Biltmore Brunch - Coral Gables, Florida The Bistro at Childress Vineyards - Lexington, North Carolina Blue Ridge - Asheville, North Carolina Boulevard Bistro- New York, New York Bravo! Restaurant and Cafe - Kalamazoo, Michigan Brennan's - New Orleans, Louisiana Café 43 - Dallas, Texas Cafe Benedicte - Houston, Texas Cafe Modern - Fort Worth, Texas Cafe Monte - Charlotte, North Carolina   Cafe Pacific – Palos Verdes, California Café Sebastienne - Kansas City, Missouri Camp Verde General Store and Restaurant - Camp Verde, Texas Canyon Cafe at Loews Ventana Canyon Resort - Tucson, Arizona Chateau Morrisette - Floyd, Virginia Chez Zee - Austin, Texas Chicken and the Egg - Marietta, Georgia Circle Brunch - The Breakers - Palm Beach, Florida Claire's at the Depot - Warrenton, Virginia The Comus Inn at Sugarloaf Mountain - Dickerson, Maryland Cooperage Inn Restaurant - Baiting Hollow (Calverton), New York Dante Next Door - Cleveland, Ohio The Davenport Signature Buffet - Spokane, Washington Deerpark Restaurant-Biltmore Estate - Asheville, North Carolina The Dining Room at Salish Lodge & Spa - Snoqualmie, Washington El Techo - San Francisco, California Eleven at Crystal Bridges - Bentonville, Arkansas Ellyngton's at the Brown Palace - Denver, Colorado Farm & Table - Albuquerque, New Mexico The Fieldhouse - Billings, Montana Freddie's Beach Bar & Restaurant - Arlington, Virginia The Frog and Turtle - Westbrook, Maine Galvez Bar & Grill - Galveston, Texas Garden Terrace at The Inverness Hotel - Englewood, Colorado Gertrude's - Baltimore - Baltimore, Maryland Golden Mast - Okauchee, Wisconsin Grand Cafe at Omni Los Angeles - Los Angeles, California Grand Dining Room at the Jekyll Island Club Hotel - Jekyll Island, Georgia Grand Finale Restaurant - Cincinnati, Ohio The Greenhouse Bistro & Market - Homosassa, Florida Harding House - Nashville, Tennessee Home Restaurant - Silver Lake - Los Angeles, California Hotel Del - Crown Room - San Diego, California The Hunt Room at the Desmond Hotel - Malvern, Pennsylvania Inn at Barley Sheaf Farm - Holicong, Pennsylvania Iron Rooster - Annapolis, Maryland Italia Trattoria - Spokane, Washington J Graham's Cafe - Louisville, Kentucky Lake Elmo Inn - Lake Elmo, Minnesota Lake Terrace - The Broadmoor - Colorado Springs, Colorado The Lakehouse - Mandeville - Mandeville, Louisiana Lilac - Billings, Montana Lucille at Drury Lane - Oak Brook, Illinois LuLu's - Richmond, Virginia M ST. Cafe - Saint Paul, Minneapolis The Magnolia Thomas Restaurant - Woodstock, Georgia Market Street Grille - Harrison, Ohio Michele's - Dover, Delaware Museum Cafe - Oklahoma City, Oklahoma Nasher Cafe - Durham, North Carolina Oasis Cafe - Salt Lake City - Salt Lake City, Utah Old Mill Room at The Boar's Head - Charlottesville, Virginia The Old School Farm To Table - Nashville, Tennessee Oxford Exchange - Tampa, Florida Palace Bar - Miami Beach, Florida The Palmetto Cafe - Charleston, South Carolina Porch Cafe - Galveston, Texas Post & Beam - Los Angeles, California Provence - Carrboro - Carrboro, North Carolina The Pump House - Fairbanks, Alaska Queen Mary Tea Room - Seattle, Washington The Rainbow Room - New York, New York Red Gravy - New Orleans, Louisiana The Regency Room - The Hotel Roanoke & Conference Center - Roanoke, Virginia Regi's American Bistro - Baltimore, Maryland Region's 117 - Lake Frederick, Virginia The Restaurant at Burdicks - Walpole, New Hampshire Restaurant Pomme - Gordonsville, Virginia Restaurant506 at The Sanford House - Arlington, Texas River Crab - St. Clair - St. Clair, Michigan The Roycroft Inn - East Aurora, New York Salty's on Alki Beach - Seattle, Washington Seasons At The Ocean House - Westerly, Rhode Island Seaview's Main Dining Room - Galloway, New Jersey SpringHouse - Alexander City, Alabama Sterling Brunch Buffet - Bally's Las Vegas - Las Vegas, Nevada Sundy House - Delray Beach, Florida Taste of Belgium - Clifton - Cincinnati, Ohio Terrain Garden Cafe - Glen Mills, Pennsylvania Timmer's Resort - West Bend, Wisconsin TJ's at The Jefferson Hotel - Richmond, Virginia V's Italiano Ristorante - Independence, Missouri The Veranda Restaurant - Fallbrook, California West Cafe - Portland, Oregon The Westgate Hotel - Sunday Brunch & Le Fontainebleau Room - San Diego, California Originally launched in November 2008, the OpenTable Reviews program helps diners find restaurants that best fit their dining occasions. Only diners who recently honored an OpenTable reservation are invited to submit restaurant reviews. Visitors to OpenTable can access reviews for thousands of OpenTable restaurant partners across the United States, Canada, Germany, Ireland, Japan and the UK.  The OpenTable Reviews program has generated more than 40 million restaurant reviews by verified diners, establishing OpenTable as one of the largest and most trusted sources for restaurant reviews. OpenTable, part of The Priceline Group (NASDAQ: PCLN), is the world's leading provider of online restaurant reservations, seating more than 21 million diners per month via online bookings across more than 40,000 restaurants. The OpenTable network connects restaurants and diners, helping diners discover and book the perfect table and helping restaurants deliver personalized hospitality to keep guests coming back. The OpenTable service enables diners to see which restaurants have available tables, select a restaurant based on verified diner reviews, menus, and other helpful information, and easily book a reservation. In addition to the company's website and mobile apps, OpenTable powers online reservations for nearly 600 partners, including many of the Internet's most popular global and local brands. For restaurants, the OpenTable hospitality solutions enable them to manage their reservation book, streamline their operations, and enhance their service levels. Since its inception in 1998, OpenTable has seated over 1 billion diners around the world.  OpenTable is headquartered in San Francisco and has bookable restaurants in more than 20 countries, including Australia, Canada, Germany, Ireland, Japan, Mexico, United Kingdom and the United States. OpenTable, OpenTable.com, OpenTable logos, and other service names are the trademarks of OpenTable, Inc. and/or its affiliates To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/opentable-reveals-100-best-brunch-restaurants-in-america-for-2017-300453426.html


News Article | May 11, 2017
Site: www.businesswire.com

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) today announced that Martin J. Madden, a longtime leader in the medical device industry, was elected to its Boards of Directors during Novocure’s 2017 annual general meeting of shareholders. In addition, Mr. Madden has been appointed to Novocure’s Audit and Nominating and Corporate Governance Committees. “We’re extremely pleased to welcome Martin to our board,” said Bill Doyle, Novocure’s Executive Chairman. “Martin’s extensive experience as a leader of medical device development and commercialization will be invaluable as we continue to execute our mission to bring a profoundly different cancer treatment to patients.” Mr. Madden recently retired after a 30-year career in medical device innovation at Johnson & Johnson. He most recently served as Vice President, Research and Development DePuy-Synthes and Vice President Medical Device R&D Transformation. Earlier in his career, Mr. Madden was a medical device engineer and innovator, and a leader of cross-functional teams charged with incubating, developing, and launching new products. Mr. Madden holds an MBA from Columbia University, a Master’s degree in Mechanical Engineering from Carnegie-Mellon University and a Bachelor’s degree in Mechanical Engineering from the University of Dayton. Mr. Madden is also a member of the Board of Directors for Microbot Medical Inc., a medical device company specializing in micro-robotic medical technologies. Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2017, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.


Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and provide a general business update.  The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event.  A replay of the webcast will be archived on the Company’s website for 30 days following the call. To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call. Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.


Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and provide a general business update.  The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event.  A replay of the webcast will be archived on the Company’s website for 30 days following the call. To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call. Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.


Ma L.,Malvern Inc. | Danoff T.M.,Malvern Inc. | Borish L.,University of Virginia
Journal of Allergy and Clinical Immunology | Year: 2014

Background Anaphylaxis is a serious allergic reaction that can cause death; however, the actual risk of death is unclear. Objective We sought to estimate the case fatality rate among hospitalizations or emergency department (ED) presentations for anaphylaxis and the mortality rate associated with anaphylaxis for the general population. Methods This was a population-based epidemiologic study using 3 national databases: the Nationwide Inpatient Sample (NIS; 1999-2009), the Nationwide Emergency Department Sample (NEDS; 2006-2009), and Multiple Cause of Death Data (MCDD; 1999-2009). Sources for these databases are hospital and ED discharge records and death certificates, respectively. Results Case fatality rates were between 0.25% and 0.33% among hospitalizations or ED presentations with anaphylaxis as the principal diagnosis (NIS+NEDS, 2006-2009). These rates represent 63 to 99 deaths per year in the United States, approximately 77% of which occurred in hospitalized patients. The rate of anaphylaxis-related hospitalizations increased from 21.0 to 25.1 per million population between 1999 and 2009 (annual percentage change, 2.23%; 95% CI, 1.52% to 2.94%), contrasting with a decreasing case fatality rate among hospitalizations (annual percentage change, -2.35%; 95% CI, -4.98% to 0.34%). Overall mortality rates ranged from 0.63 to 0.76 per million population (186-225 deaths per year, MCDD) and appeared stable in the last decade (annual percentage change, -0.31%; 95% CI, -1.54% to 0.93%). Conclusion From 2006 to 2009, the overwhelming majority of hospitalizations or ED presentations for anaphylaxis did not result in death, with an average case fatality rate of 0.3%. Anaphylaxis-related hospitalizations increased steadily in the last decade (1999-2009), but this increase was offset by the decreasing case fatality rate among those hospitalized; both inpatient and overall mortality rates associated with anaphylaxis appeared stable and were well under 1 per million population. Although anaphylactic reactions are potentially life-threatening, the probability of dying is actually very low. With the prevalence of anaphylaxis on the increase, practitioners need to stay vigilant and follow the treatment guidelines to further reduce anaphylaxis-related deaths. © 2013 American Academy of Allergy, Asthma & Immunology.

Loading Malvern Inc. collaborators
Loading Malvern Inc. collaborators